REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II
Rhea-AI Summary
REGENXBIO (Nasdaq:RGNX) announced agreement with the FDA on the path to resubmit its BLA for NAVSUNLI™, a potential one-time gene therapy for MPS II (Hunter syndrome). No additional studies or new patients are required, and the FDA plans an expedited review.
A Type A meeting is expected in July, with BLA resubmission targeted for Q3 2026.
AI-generated analysis. Not financial advice.
Positive
- FDA agrees existing NAVSUNLI data can support accelerated approval review
- No additional NAVSUNLI studies or patient enrollment required by FDA
- FDA plans expedited review of NAVSUNLI BLA resubmission and rapid labeling talks
- Type A FDA meeting expected July 2026 to review longer-term data
- BLA resubmission for NAVSUNLI targeted by company for Q3 2026
Negative
- NAVSUNLI previously received a Complete Response Letter in February 2026
- NAVSUNLI approval timing remains uncertain pending Q3 2026 BLA resubmission and review
News Market Reaction – RGNX
On the day this news was published, RGNX gained 18.20%, reflecting a significant positive market reaction. Argus tracked a peak move of +29.1% during that session. Our momentum scanner triggered 48 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $82M to the company's valuation, bringing the market cap to $534.55M at that time.
Data tracked by StockTitan Argus on the day of publication.
Peers on Argus
RGNX was flagged as moving up while close peers showed mixed performance: ARCT and REPL were up modestly, whereas ATYR, BCYC, and KOD traded lower, suggesting a stock-specific driver.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 18 | Investor conferences | Neutral | -1.1% | Participation in upcoming investor healthcare conferences and related webcasts. |
| May 14 | Earnings and milestones | Negative | -37.8% | Q1 2026 results with lower revenue and sizable net loss despite milestones. |
| May 14 | Phase III topline data | Positive | -37.8% | Pivotal RGX-202 Phase III met primary endpoint with strong efficacy and safety. |
| May 07 | Scientific meeting abstracts | Positive | +2.0% | Multiple presentations at ASGCT 2026 on RGX-202 and platform advances. |
| May 06 | Webcast announcement | Positive | +10.8% | Planned webcast to discuss pivotal RGX-202 results and Q1 2026 earnings. |
Past news has sometimes triggered sharp downside, including a large selloff despite positive Phase III data.
Regulatory & Risk Context
Short positioning appears elevated, implying potential for heightened volatility if sentiment changes abruptly.
An effective S-3 shelf lets the company issue up to the registered amount over time, which can provide funding flexibility but may be dilutive when utilized.
Market Pulse Summary
The stock surged +18.2% in the session following this news. A strong positive reaction aligns with prior enthusiasm for regulatory milestones and rare-disease gene therapies. However, elevated short interest and existing shelf capacity could cap follow-through if investors refocus on dilution or execution risks.
Key Terms
accelerated approval regulatory
complete response letter regulatory
type a meeting regulatory
biologics license application regulatory
biomarker medical
gene therapy medical
AI-generated analysis. Not financial advice.
- FDA confirmed no additional studies required, existing longer-term data from the CAMPSIITE® study will be reviewed on an expedited basis for approval via the accelerated approval pathway
- The Company expects to resubmit the BLA in Q3 2026
Through a recent collaborative discussion, as part of the Company's appeal of the February 2026 NAVSUNLI Complete Response Letter, the FDA acknowledged the existing NAVSUNLI clinical data is sufficient to be considered for the accelerated approval pathway and that the Company does not need to enroll additional patients or conduct additional studies, including the FDA's previously recommended incorporation of an untreated control arm. The FDA asked the Company to request a Type A meeting to review existing longer-term biomarker and clinical data and to resubmit the Biologics License Application (BLA) following this meeting. The FDA stated that it would review REGENXBIO's resubmission on an expedited basis, with labeling discussions to begin shortly following the resubmission. The FDA emphasized its commitment to advancing new therapies for rare diseases under the accelerated approval pathway.
REGENXBIO expects the Type A meeting to take place in July and to resubmit the BLA rapidly following the meeting in Q3 2026.
"We are encouraged by recent signals from the new FDA leadership reinforcing a commitment to address the unique nature of rare diseases and use the accelerated approval pathway to bring transformative therapies to patients with serious, unmet medical needs," said Curran Simpson, President and CEO of REGENXBIO. "We will continue to work closely with the FDA and remain focused on bringing this important therapy to boys living with Hunter syndrome as quickly as possible."
"Hunter syndrome is a devastating, progressive disease with significant unmet medical needs and we are thrilled to see this progress for NAVSUNLI," said Scott Loiler, Ph.D., Chief Scientific Officer National MPS Society. "The MPS community urgently needs new treatment options, and we appreciate the FDA's willingness to use the accelerated approval pathway for rare diseases and expedite the review of NAVSUNLI so that the Hunter syndrome community may soon have access to a potentially transformative one-time treatment."
About Mucopolysaccharidosis Type II (MPS II)
MPS II, or Hunter Syndrome, is a rare, X-linked recessive disease caused by a deficiency in the lysosomal enzyme I2S leading to an accumulation of glycosaminoglycans (GAGs), including heparan sulfate (HS) in tissues which ultimately results in cell, tissue, and organ dysfunction, including in the CNS. Approximately 2,000 patients worldwide are diagnosed with MPS II, with more than 500 babies born annually around the world with the disease. The majority of MPS II patients have severe forms of the disease, with which early developmental milestones may be met, but developmental delay is readily apparent by 18 to 24 months. CSF HS is a key disease biomarker in MPS II patients. Among its quantified disaccharides, D2S6 has been shown to correlate with neurocognitive manifestations, highlighting its role as a clinically relevant biomarker of disease severity and therapeutic response.
About NAVSUNLI (clemidsogene lanparvovec- sngl)
NAVSUNLI is a one-time investigational gene therapy for the treatment of boys with MPS II, designed to deliver the iduronate-2-sulfatase (IDS) gene to the central nervous system (CNS). Delivery of the IDS gene within cells in the CNS could provide a permanent source of secreted iduronate-2-sulfatase (I2S) protein beyond the blood-brain barrier, allowing for long-term cross correction of cells throughout the CNS. NAVSUNLI expressed protein is structurally identical to normal I2S.
NAVSUNLI has received Orphan Drug Product, Rare Pediatric Disease, Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations from the U.S. Food and Drug Administration and advanced therapy medicinal products (ATMP) classification from the European Medicines Agency.
Under the strategic partnership announced in January 2025, following potential FDA approval, RGX-121 will be commercialized by NS Pharma, Inc., a wholly-owned subsidiary of Nippon Shinyaku, in the U.S. Approval of NAVSUNLI could result in receipt of a Priority Review Voucher (PRV). REGENXBIO retains all rights to, and 100 percent of any proceeds related to the potential sale of, the PRV.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie, and NAVSUNLI™ (clemidsogene lanparvovec-sngl, RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.REGENXBIO.com.
FORWARD-LOOKING STATEMENTS
This press release includes "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as "believe," "may," "will," "estimate," "continue," "anticipate," "assume," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would" or by variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things, REGENXBIO's future operations, clinical trials, costs and cash flow. REGENXBIO has based these forward-looking statements on its current expectations and assumptions and analyses made by REGENXBIO in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO's expectations and predictions is subject to a number of risks and uncertainties, FDA's review process, the success of clinical trials conducted by REGENXBIO, the ability to obtain and maintain regulatory approval of product candidates, and other factors, many of which are beyond the control of REGENXBIO. Refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of REGENXBIO's Annual Report on Form 10-K for the year ended December 31, 2025, and comparable "risk factors" sections of REGENXBIO's Quarterly Reports on Form 10-Q and other filings, which have been filed with the SEC and are available on the SEC's website at WWW.SEC.GOV. All of the forward-looking statements made in this press release are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on REGENXBIO or its businesses or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to rely too heavily on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this press release. Except as required by law, REGENXBIO does not undertake any obligation, and specifically declines any obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Zolgensma® is a registered trademark of Novartis Gene Therapies. All other trademarks referenced herein are registered trademarks of REGENXBIO.
CONTACTS:
Dana Cormack
Corporate Communications
Dcormack@regenxbio.com
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-alignment-with-fda-on-path-forward-for-navsunli-bla-resubmission-for-accelerated-approval-first-potential-gene-therapy-for-mps-ii-302806010.html
SOURCE REGENXBIO Inc.